Breaking News Instant updates and real-time market news.

BIIB

Biogen

$251.74

-3.28 (-1.29%)

, CLVS

Clovis

$59.97

0.27 (0.45%)

10:38
06/19/17
06/19
10:38
06/19/17
10:38

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Neutral from Sell at UBS with analyst Carter Gould saying he sees an improved risk/reward and a positive near-term setup going into the second quarter earnings call and strategic review. 2. Clovis (CLVS) upgraded to Neutral from Sell at Chardan. 3. Cedar Fair (FUN) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Christopher Prykull saying early season indicators appear strong as several management teams noted ongoing leisure strength at the firm's Lodging, Gaming Restaurant and Leisure Conference. 4. Athene Holding (ATH) upgraded to Outperform from Neutral at Credit Suisse with analyst John Nadel saying he believes the probability is increasing that Athene will use acquisitions to accelerate its balance sheet and earnings growth. 5. Credit Suisse (CS) upgraded to Buy from Hold at Deutsche Bank with analyst Kinner Lakhani saying an inflection in the company's operating results is near following the recent anticipated capital raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

BIIB

Biogen

$251.74

-3.28 (-1.29%)

CLVS

Clovis

$59.97

0.27 (0.45%)

FUN

Cedar Fair

$71.83

1.15 (1.63%)

ATH

Athene Holding

$49.74

0.87 (1.78%)

CS

Credit Suisse

$14.01

0.4653 (3.44%)

BIIB Biogen
$251.74

-3.28 (-1.29%)

06/14/17
MSCO
06/14/17
NO CHANGE
MSCO
Alexion new CFO 'highly credible,' should calm investors, says Morgan Stanley
After Alexion (ALXN) named Biogen (BIIB) CFO Paul Clancy as its new CFO, Morgan Stanley analyst Matthew Harrison calls Clancy "a highly credible choice." Harrison thinks that the appointment of Clancy should ease investors' fears about the "stability" of the company's Soliris drug. The analyst adds that the CEO's forecast for "double digit growth," along with Clancy's appointment, should boost the stock today. He keeps a $138 price target and Overweight rating on the shares.
06/14/17
FBCO
06/14/17
NO CHANGE
Target $164
FBCO
Outperform
Former Biogen CFO a 'strong hire' for Alexion, says Credit Suisse
Credit Suisse analyst Alethia Young said Alexion's (ALXN) poaching of biopharma CFO veteran Paul Clancy from Biogen (BIIB) is a strong hire for the former and a loss for the operations of the latter. She expects Alexion shares to be higher today, and for Biogen to be weak, following the news. Young keeps an Outperform rating on Alexion.
06/14/17
UBSW
06/14/17
NO CHANGE
Target $140
UBSW
Buy
Alexion CFO a significant hire, says UBS
UBS analyst Martin Auster noted Alexion (ALXN) hired Biogen's (BIIB) Paul Clancy as CFO and believes it has a positive read-through as he is well known by the Street and is received favorably. The analyst also believes the company can restore value through a combination of execution on growth drivers and a reduction of its implied risk premium in light of recent regulatory headwinds. Auster reiterated his Buy rating and $140 price target on Alexion shares.
06/19/17
UBSW
06/19/17
UPGRADE
Target $270
UBSW
Neutral
Biogen upgraded to Neutral from Sell at UBS
UBS analyst Carter Gould upgraded Biogen to Neutral and raised his price target for the shares to $270 from $262. The biotech closed Friday down $3.28 from $251.74. The analyst sees an improved risk/reward and a positive near-term setup going into the Q2 earnings call and strategic review. The competitive threat to Biogen's Spinraza from gene therapy is now priced into the shares and sentiment is near a bottom, Gould tells investors in a research note. The analyst is also "incrementally more constructive" on aducanumab. Gould thinks the stock's underperformance "stops here."
CLVS Clovis
$59.97

0.27 (0.45%)

06/19/17
CHDN
06/19/17
UPGRADE
CHDN
Neutral
Clovis upgraded to Neutral from Sell at Chardan
06/19/17
STFL
06/19/17
NO CHANGE
Target $125
STFL
Buy
Clovis price target raised to $125 from $86 at Stifel
06/19/17
RAJA
06/19/17
NO CHANGE
RAJA
Market Perform
Raymond James remains cautious on Tesaro, takeout less likely
Raymond James analyst Christopher Raymond remains cautious on Tesaro (TSRO) shares following Clovis' (CLVS) Rubraca ARIEL3 results. The analyst said PFS measures between the Clovis Rubraca and Tesaro's Zejula are remarkably similar among ovarian cancer patients, making the PARP space much more competitive and crowded. Raymond believes a takeout of Tesaro based on Zejula's superior labeling is much less likely and reiterated his Market Perform rating on shares.
06/19/17
JEFF
06/19/17
NO CHANGE
Target $124
JEFF
Hold
Tesaro worth $80 per share on fundamentals, says Jefferies
Jefferies analyst Eun Yang views Clovis Oncology's (CLVS) data today for rucaparib as "highly competitive" to Tesaro's (TSRO) niraparib. The data from Clovis will likely impact any potential takeover premium for Tesaro, Yang tells investors in a research note. The analyst views Tesaro as being worth $80 per share on a fundamental basis. She has a Hold rating and $124 price target on the shares. Tesaro in early trading is down 5%, or $7.09, to $137.22.
FUN Cedar Fair
$71.83

1.15 (1.63%)

04/21/17
STFL
04/21/17
INITIATION
STFL
Buy
Cedar Fair initiated at Stifel
As noted earlier, Stifel started coverage of Cedar Fair with a $78 price target and a Buy rating. Stifel analyst Steven Wieczynski says that the company has delivered consistent results, while its planned utilization of additional land should enable its EBITDA growth to accelerate over the longer term. He thinks that the stock can deliver "sustainable upper-single to low-double digit total returns in perpetuity."
04/20/17
STFL
04/20/17
INITIATION
Target $78
STFL
Buy
Cedar Fair initiated with a Buy at Stifel
Stifel initiated Cedar Fair with a Buy and a $78 price target.
04/21/17
04/21/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Plains All American (PAA) initiated with an Outperform at Macquarie. 2. Wendy's (WEN) and McDonald's (MCD) were initiated with an Outperform at BMO Capital while Yum! Brands (YUM) was initiated with a Market Perform. 3. Cedar Fair (FUN), Six Flags (SIX), and SeaWorld (SEAS) were initiated with a Buy at Stifel. 4. Domino's Pizza (DPZ) initiated with a Buy at Guggenheim. 5. Cidara Therapeutics (CDTX) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/17
GSCO
06/19/17
UPGRADE
GSCO
Conviction Buy
Cedar Fair upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman analyst Christopher Prykull added Cedar Fair to the Conviction Buy List with an $81 price target telling investors early season indicators appear strong as several management teams noted ongoing leisure strength at the firm's Lodging, Gaming Restaurant and Leisure Conference. The analyst has increased confidence in its above consensus estimates and said weather has improved post Memorial Day.
ATH Athene Holding
$49.74

0.87 (1.78%)

04/03/17
MSCO
04/03/17
UPGRADE
Target $58
MSCO
Overweight
Athene Holding upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Nigel Dally upgraded Athene Holding to Overweight and raised his price target for the shares to $58 from $54. The analyst cites the recent pullback in the shares as well the company's growth and profitability, which he says is "well ahead" of peers.
04/04/17
04/04/17
UPGRADE
Target $58

Overweight
Athene Holding upgraded on profitability and growth at Morgan Stanley
As previously reported, Morgan Stanley upgraded Athene Holding to Overweight from Equal Weight with a $58 price target. Analyst Nigel Dally told investors Athene is poised for growth and profitability well ahead of its peers, driven by product expansion and distribution, and said the recent pullback provides solid upside potential.
06/19/17
FBCO
06/19/17
UPGRADE
Target $66
FBCO
Outperform
Athene Holding upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst John Nadel upgraded Athene Holding to Outperform and raised his price target for the shares to $66 from $55. The analyst believes the probability is increasing that Athene will use acquisitions to accelerate its balance sheet and earnings growth. Further, following the recent upgrade by AM Best, the company is better positioned to participate in the "growing pension risk transfer opportunity."
04/04/17
MSCO
04/04/17
UPGRADE
MSCO
Overweight
Athene Holding upgraded to Overweight from Equal Weight at Morgan Stanley
CS Credit Suisse
$14.01

0.4653 (3.44%)

02/17/17
02/17/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Workday (WDAY) upgraded to Overweight from Neutral at Piper Jaffray by analyst Alex Zukin, who said his channel checks indicate the company's fundamentals have improved materially since last quarter. He notes that his checks on Workday and Salesforce (CRM) "came back the strongest in recent memory." 2. Tempur Sealy (TPX) upgraded to Outperform from Market Perform at Raymond James, as analyst Budd Bugatch said all the bad news is known and the improvement in revenues and earnings will become more visible as 2017 unfolds. 3. Capital One (COF) upgraded to Buy from Neutral at Goldman Sachs by analyst Ryan Nash, who raised his price target for the shares to $110 from $106. Almost all of the bank's increases in losses during 2016 can be explained by "growth math," which should have a "finite life to it," Nash tells investors. 4. Credit Suisse (CS) upgraded to Overweight from Equal Weight at Morgan Stanley by analyst Magdalena Stoklosa, who thinks connectivity across businesses, capital utilization, and earnings quality from here will result in more predictable earnings. 5. Chemours (CC) upgraded to Positive at Susquehanna by analyst Don Carson, who sees significant upside he sees to management's modest EBITDA guidance due to greater momentum in TiO2 prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/17
DBAB
06/19/17
UPGRADE
DBAB
Buy
Credit Suisse upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Kinner Lakhani upgraded Credit Suisse to Buy with a CHF 15 price target. An inflection in the company's operating results is near following the recent anticipated capital raise, the analyst contends.
06/19/17
BOFA
06/19/17
INITIATION
Target $17.19
BOFA
Buy
Credit Suisse resumed with a Buy at BofA/Merrill
BofA/Merrill analyst Andrew Stimpson resumed coverage on Credit Suisse with a Buy and a $17.20 price target.
02/17/17
MSCO
02/17/17
UPGRADE
MSCO
Overweight
Credit Suisse upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Magdalena Stoklosa upgraded Credit Suisse to Overweight saying connectivity across businesses, capital utilization, and earnings quality from here will result in more predictable earnings delivery.

TODAY'S FREE FLY STORIES

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.